FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313897822> ?p ?o ?g. }

• W4313897822 endingPage "146" @default.
• W4313897822 startingPage "146" @default.
• W4313897822 abstract "Triple-negative breast cancer (TNBC) is the subtype of breast cancer with the poorest outcomes, and is associated with a high risk of relapse and metastasis. The treatment choices for this malignancy have been confined to conventional chemotherapeutic agents, due to a lack of expression of the canonical molecular targets. Immunotherapy has been recently changing the treatment paradigm for many types of tumors, and the approach of evoking active immune responses in the milieu of breast tumors through cancer vaccines has been introduced as one of the most novel immunotherapeutic approaches. Accordingly, a number of vaccines for the treatment or prevention of recurrence have been developed and are currently being studied in TNBC patients, while none have yet received any approvals. To elucidate the efficacy and safety of these vaccines, we performed a systematic review of the available literature on the topic. After searching the PubMed, Scopus, Web of Science, Embase, Cochrane CENTRAL, and Google Scholar databases, a total of 5701 results were obtained, from which 42 clinical studies were eventually included based on the predefined criteria. The overall quality of the included studies was acceptable. However, due to a lack of reporting outcomes of survival or progression in some studies (which were presented as conference abstracts) as well as the heterogeneity of the reported outcomes and study designs, we were not able to carry out a meta-analysis. A total of 32 different vaccines have so far been evaluated in TNBC patients, with the majority belonging to the peptide-based vaccine type. The other vaccines were in the cell or nucleic acid (RNA/DNA)-based categories. Most vaccines proved to be safe with low-grade, local adverse events and could efficiently evoke cellular immune responses; however, most trials were not able to demonstrate significant improvements in clinical indices of efficacy. This is in part due to the limited number of randomized studies, as well as the limited TNBC population of each trial. However, due to the encouraging results of the currently published trials, we anticipate that this strategy could show its potential through larger, phase III randomized studies in the near future." @default.
• W4313897822 created "2023-01-10" @default.
• W4313897822 creator A5020072638 @default.
• W4313897822 creator A5043880029 @default.
• W4313897822 creator A5048119520 @default.
• W4313897822 creator A5075417892 @default.
• W4313897822 creator A5075984245 @default.
• W4313897822 creator A5084164739 @default.
• W4313897822 creator A5040357242 @default.
• W4313897822 date "2023-01-09" @default.
• W4313897822 modified "2023-10-14" @default.
• W4313897822 title "Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review" @default.
• W4313897822 cites W1485026692 @default.
• W4313897822 cites W1593582113 @default.
• W4313897822 cites W1640635403 @default.
• W4313897822 cites W1865272626 @default.
• W4313897822 cites W1866903156 @default.
• W4313897822 cites W1966308488 @default.
• W4313897822 cites W1974965248 @default.
• W4313897822 cites W1980206212 @default.
• W4313897822 cites W1980785423 @default.
• W4313897822 cites W1985558623 @default.
• W4313897822 cites W1992343552 @default.
• W4313897822 cites W1993951035 @default.
• W4313897822 cites W1997112179 @default.
• W4313897822 cites W2000577029 @default.
• W4313897822 cites W2006629572 @default.
• W4313897822 cites W2013843303 @default.
• W4313897822 cites W2014805757 @default.
• W4313897822 cites W2016488466 @default.
• W4313897822 cites W2033174123 @default.
• W4313897822 cites W2034451570 @default.
• W4313897822 cites W2035144728 @default.
• W4313897822 cites W2037665874 @default.
• W4313897822 cites W2044535505 @default.
• W4313897822 cites W2045927502 @default.
• W4313897822 cites W2049729316 @default.
• W4313897822 cites W2049786239 @default.
• W4313897822 cites W2053029599 @default.
• W4313897822 cites W2060727677 @default.
• W4313897822 cites W2063382533 @default.
• W4313897822 cites W2071244674 @default.
• W4313897822 cites W2073114277 @default.
• W4313897822 cites W2078684250 @default.
• W4313897822 cites W2083836322 @default.
• W4313897822 cites W2086493960 @default.
• W4313897822 cites W2094060692 @default.
• W4313897822 cites W2095156669 @default.
• W4313897822 cites W2096038417 @default.
• W4313897822 cites W2101030466 @default.
• W4313897822 cites W2104599421 @default.
• W4313897822 cites W2108177250 @default.
• W4313897822 cites W2108944797 @default.
• W4313897822 cites W2111912457 @default.
• W4313897822 cites W2112887207 @default.
• W4313897822 cites W2118437069 @default.
• W4313897822 cites W2122971334 @default.
• W4313897822 cites W2123501358 @default.
• W4313897822 cites W2125697254 @default.
• W4313897822 cites W2126043466 @default.
• W4313897822 cites W2128083415 @default.
• W4313897822 cites W2128233608 @default.
• W4313897822 cites W2136211316 @default.
• W4313897822 cites W2139619113 @default.
• W4313897822 cites W2147210428 @default.
• W4313897822 cites W2149647856 @default.
• W4313897822 cites W2153935963 @default.
• W4313897822 cites W2155240407 @default.
• W4313897822 cites W2160953048 @default.
• W4313897822 cites W2161872048 @default.
• W4313897822 cites W2165835640 @default.
• W4313897822 cites W2170602872 @default.
• W4313897822 cites W2171187777 @default.
• W4313897822 cites W2285186666 @default.
• W4313897822 cites W2293327002 @default.
• W4313897822 cites W2326870002 @default.
• W4313897822 cites W2328399718 @default.
• W4313897822 cites W2329334730 @default.
• W4313897822 cites W2329659234 @default.
• W4313897822 cites W2333043919 @default.
• W4313897822 cites W2339120759 @default.
• W4313897822 cites W2394769381 @default.
• W4313897822 cites W2397982427 @default.
• W4313897822 cites W2429491288 @default.
• W4313897822 cites W2430802687 @default.
• W4313897822 cites W2480252091 @default.
• W4313897822 cites W2504828590 @default.
• W4313897822 cites W2507448865 @default.
• W4313897822 cites W2515734953 @default.
• W4313897822 cites W2560367415 @default.
• W4313897822 cites W2564146672 @default.
• W4313897822 cites W2595052553 @default.
• W4313897822 cites W2596107133 @default.
• W4313897822 cites W2597744894 @default.
• W4313897822 cites W2598449944 @default.
• W4313897822 cites W2599096610 @default.
• W4313897822 cites W2599301244 @default.
• W4313897822 cites W2619514029 @default.

• next